← VERTEX PHARMACEUTICALS INC / MA
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying Value | $1.2b | $1.7b | $2.7b | $3.1b | $6.0b | $6.8b | $10.5b | $10.4b | $4.6b | $5.1b | |
| Prepaid Expense and Other Assets, Current | $70.5m | $165.6m | $140.8m | $213.5m | $308.4m | $545.8m | $553.5m | $623.7m | $665.7m | $853.3m | |
| Inventory, Net | $77.6m | $111.8m | $124.4m | $167.5m | $280.8m | $353.1m | $460.6m | $738.8m | $1.2b | $1.7b | |
| Assets, Current | $1.8b | $2.6b | $3.8b | $4.8b | $8.1b | $9.6b | $13.2b | $14.1b | $9.6b | $11.2b | |
| Property, Plant and Equipment, Net | $698.4m | $789.4m | $812.0m | $745.1m | $958.5m | $1.1b | $1.1b | $1.2b | $1.2b | $1.5b | |
| Goodwill | $50.4m | $50.4m | $50.4m | $1.0b | $1.0b | $1.0b | $1.1b | $1.1b | $1.1b | $1.1b | |
| Intangible Assets, Net (Excluding Goodwill) | — | — | — | $400.0m | $400.0m | $400.0m | $603.6m | $839.9m | $825.9m | $424.2m | |
| Operating Lease, Right-of-Use Asset | — | — | — | $88.2m | $325.6m | $330.3m | $347.4m | $293.6m | $1.4b | $1.6b | |
| Other Assets, Noncurrent | $11.8m | $7.8m | $40.7m | $157.6m | $49.4m | $110.8m | $521.8m | $895.3m | $999.3m | $1.2b | |
| Additional Financial Items | |||||||||||
| Accounts Receivable, after Allowance for Credit Loss, Current | $201.1m | $281.3m | $409.7m | $633.5m | $885.4m | $1.1b | $1.4b | $1.6b | $1.6b | $2.1b | |
| Accrued Liabilities, Current | $315.2m | $444.0m | $604.5m | $1.1b | $1.4b | $1.7b | $2.1b | $2.7b | $2.8b | $3.0b | |
| Assets | $2.9b | $3.5b | $6.2b | $8.3b | $11.8b | $13.4b | $18.2b | $22.7b | $22.5b | $25.6b | |
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Operating Lease, Liability, Current | — | — | — | $11.5m | $10.5m | $33.3m | $48.6m | $33.1m | $87.1m | $77.3m | |
| Accounts Payable, Current | $61.5m | $74.0m | $111.0m | $87.6m | $155.1m | $195.0m | $303.9m | $364.9m | $413.0m | $461.7m | |
| Operating Lease, Liability, Noncurrent | — | — | — | $84.3m | $350.5m | $377.4m | $379.5m | $348.6m | $1.5b | $1.8b | |
| Deferred Revenue, Current | $6.0m | $5.2m | — | — | — | — | — | — | — | — | |
| Deferred Revenue, Noncurrent | $6.6m | $1.7m | — | — | — | — | — | — | — | — | |
| Liabilities, Current | $792.5m | $807.3m | $1.1b | $1.3b | $1.9b | $2.1b | $2.7b | $3.5b | $3.6b | $3.9b | |
| Other Liabilities, Noncurrent | $102.1m | $26.0m | $26.3m | $183.3m | $108.4m | $116.8m | $685.8m | $877.7m | $901.8m | $1.3b | |
| Deferred Tax Liabilities, Net | $133.7m | $5.5m | — | — | — | — | — | — | — | — | |
| Liabilities | $1.6b | $1.5b | $1.8b | $2.2b | $3.1b | $3.3b | $4.2b | $5.1b | $6.1b | $7.0b | |
| Commitments and Contingencies | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| Stockholders’ equity: | |||||||||||
| Preferred Stock, Value, Issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Common Stock, Value, Issued | $2.5m | $2.5m | $2.5m | $2.6m | $2.6m | $2.5m | $2.6m | $2.6m | $2.6m | $2.5m | |
| Retained Earnings (Accumulated Deficit) | ($5.4b) | ($5.1b) | ($3.0b) | ($1.9b) | $858.7m | $3.2b | $6.5b | $10.1b | $9.6b | $13.6b | |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | $21.2m | ($11.6m) | $659k | ($2.0m) | ($68.5m) | $15.9m | $800k | ($14.3m) | $127.8m | ($15.9m) | |
| Additional Paid in Capital, Common Stock | $6.5b | $7.2b | $7.4b | $7.9b | $7.9b | $6.9b | $7.4b | $7.4b | $6.7b | $5.1b | |
| Stockholders' Equity Attributable to Parent | $1.2b | $2.0b | $4.4b | — | — | $10.1b | $13.9b | $17.6b | $16.4b | $18.7b | |
| Stockholders' Equity Attributable to Noncontrolling Interest | $181.6m | $13.7m | $0 | — | — | — | — | — | — | — | |
| Liabilities and Equity | $2.9b | $3.5b | $6.2b | $8.3b | $11.8b | $13.4b | $18.2b | $22.7b | $22.5b | $25.6b |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.